Hansson, O; Rutz, S; Zetterberg, H; Bauer, E; Hähl, T; Manuilova, E; Mert, MC; ... Stomrud, E; + view all Hansson, O; Rutz, S; Zetterberg, H; Bauer, E; Hähl, T; Manuilova, E; Mert, MC; Wahl, S; Blennow, K; Stomrud, E; - view fewer (2020) Pre-analytical protocol for measuring Alzheimer's disease biomarkers in fresh CSF. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring , 12 (1) , Article e12137. 10.1002/dad2.12137.

Preview

Text DAD2-12-e12137.pdf - Accepted Version Download (706kB) | Preview

Abstract

INTRODUCTION: We aimed to establish a standardized, routine‐use pre‐analytical protocol for measuring Alzheimer's disease (AD) biomarkers in cerebrospinal fluid (CSF). METHODS: The effect of pre‐analytical factors (sample collection/handling/storage/transportation) on biomarker levels was assessed using freshly collected CSF. Tube type/sterilization was assessed using previously frozen samples. A low‐bind false‐bottom tube (FBT, Sarstedt) was used for all experiments, except tube types/sterilization experiments. Biomarkers were measured using Elecsys CSF assays. RESULTS: Amyloid beta (Aβ)_{1-42} levels varied by tube type, using a low‐bind FBT reduced variation. Aβ_{1-42} levels were higher with no mixing versus roller/inversion mixing. Aβ_{1-42} levels were lower with horizontal versus upright transportation; this was resolved by maximal tube filling and storage at 2°C to 8°C. Aβ1‐40 levels were less strongly affected. Phospho‐tau and total‐tau levels were largely unaffected. DISCUSSION: We propose an easy‐to‐use, standardized, routine‐use pre‐analytical protocol, using low‐bind FBTs, for measuring AD CSF biomarkers in clinical practice.

Download activity - last month

Export as JSONXMLCSV

Download activity - last 12 months

Export as CSVXMLJSON

Downloads by country - last 12 months

Export as CSVJSONXML

Archive Staff Only

View Item